BiotechTube

Bevacizumab

Phase 2Recruiting
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anaplastic (Malignant) Meningioma

Conditions

Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma, Grade III Meningioma, Recurrent Meningioma, Supratentorial Meningioma

Trial Timeline

Aug 1, 2016 → Dec 1, 2026

NCT ID
NCT02847559

About Bevacizumab

Bevacizumab is a phase 2 stage product being developed by Novocure for Anaplastic (Malignant) Meningioma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT02847559. Target conditions include Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (4)

NCT IDPhaseStatus
NCT02743078Phase 2Terminated
NCT02663271Phase 2Terminated
NCT02847559Phase 2Recruiting
NCT01894061Phase 2Completed

Competing Products

20 competing products in Anaplastic (Malignant) Meningioma

See all competitors
ProductCompanyStageHype Score
CS-7017 + PaclitaxelDaiichi SankyoPhase 1/2
41
efatutazone + paclitaxelDaiichi SankyoPhase 2
52
Lenvatinib 24 mgEisaiPhase 2
52
Lenvatinib + NivolumabOno PharmaceuticalPhase 2
52
durvalumab + tremelimumabAstraZenecaPhase 1
33
PembrolizumabMerckPhase 2
52
LDK378 + AUY922NovartisPhase 1
33
ceritinibNovartisPre-clinical
23
LDK378NovartisPhase 1
33
CeritinibNovartisPhase 2
52
Gemcitabine + ribociclib + sonidegib + trametinib + filgrastimNovartisPhase 1
33
dabrafenib/trametinibNovartisPhase 2
52
Trametinib + PaclitaxelNovartisPhase 1
33
Alectinib + CrizotinibRochePhase 3
77
Sunitinib MalatePfizerPhase 2
51
Crizotinib (PF-02341066)PfizerPhase 2
51
LorlatinibPfizerPhase 2
51
CrizotinibPfizerPhase 1/2
40
Cemiplimab + XL092Regeneron PharmaceuticalsPhase 1
32
Etirinotecan pegolNektar TherapeuticsPhase 2
47

Other Products from Novocure

PaclitaxelPhase 3
72
Pembrolizumab + Platinum based chemotherapyPhase 3
72
Gemcitabine + nab paclitaxelPhase 3
72
TemozolomidePhase 3
72
Immune checkpoint inhibitors or docetaxelPhase 3
72